Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Restresses Risk of HBV Reactivation for 8 Hep C Drugs
June 29, 2016
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
- Registration System for Prevention of Dementia to Begin Operation; Will Provide Info on Clinical Research, Trials
June 24, 2016
- MHLW Official Vows to Swiftly Present Proposal on “Optimal Use of Innovative Drugs”: Chuikyo
June 23, 2016
- Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya
June 23, 2016
- Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well
June 22, 2016
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
- MHLW Unveils List of Switch OTCs Eligible for Tax Break
June 20, 2016
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
- MHLW Reprimands Bipha Over Leakage of Recombinant Organisms in Manufacturing Process for Medway Injection
June 20, 2016
- Kaketsuken-Like Cases Seen Outside Japan Too, Many Exposed through Tip-Offs: PMDA
June 17, 2016
- MHLW Study Group Approves Interim Report toward Full-Scale Operation of MID-NET Database
June 17, 2016
- First Generics for 8 APIs to Join NHI Price List on June 17, 40% Price Rule Applied to Olanzapine
June 16, 2016
- Greater than Expected Need for Drug Discovery Research Using Existing Drugs: AMED Project
June 16, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…